Vanguard Capital Management
SYRE icon

Vanguard Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Vanguard Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306M Buy
3,448,681
+391,280
+13% +$28.6M 0.01% 912
2026
Q1 		$154M Buy
+3,057,401
New +$115M ﹤0.01% 1225

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's SYRE Position: Q2 2026 in Review

Vanguard Capital Management increased its Spyre Therapeutics (SYRE) stake by 13% in Q2 2026, buying an estimated $28.6M and bringing the position to 3,448,681 shares worth $306M. The position accounts for 0.01% of the portfolio, ranked #912.

Vanguard Capital Management first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 237 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Vanguard Capital Management held 3,448,681 shares of Spyre Therapeutics worth $306M as of Q2 2026.
  • Vanguard Capital Management bought 391,280 Spyre Therapeutics shares in Q2 2026, an estimated $28.6M.
  • Spyre Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #912 holding.
  • Vanguard Capital Management first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 237 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.